Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
In study B, individuals with T2DM randomly received GLP-1 RA liraglutide (titrated up to 1.8 mg daily) or titrated insulin glargine for 12 wk.
|
31415908 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
GLP-1 also controls glucose homeostasis, which lead to the approval of GLP-1 receptor agonists for treatment of diabetes type II.
|
31759971 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
While these data suggest the potential of small molecule GLP-1R PAMs for T2DM treatment, further optimization is still required towards a clinical candidate.
|
31596080 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Whilst such effects of GIP antagonism are yet to be evaluated in humans, recent studies using combined GIP and GLP-1 agonists have shown weight reduction and improved glycaemic control in people with type 2 diabetes (T2D).
|
31759125 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Next, we present the results from major randomized controlled trials on the use of GLP-1 receptor agonists for managing type 2 diabetes, and emerging data on treating obesity and prediabetes.
|
31392745 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
The lamprey GLP-1 analogue shows therapeutic promise for treatment of patients with obesity-related Type 2 diabetes.
|
31539596 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
A randomized, double-blind, placebo-controlled, 4-week phase 1 multiple-ascending-dose study (NCT02411825) in 36 overweight to obese subjects with type 2 diabetes mellitus receiving SAR425899 demonstrated decreased body weight with a safety profile comparable with GLP-1R agonists.
|
31808298 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment's ability to reduce glycated haemoglobin and their associated weight loss and low risk for hypoglycaemia.
|
31801807 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Liraglutide is a GLP-1 receptor agonist recently approved for Type-II diabetes (T2D) treatment with superior hypoglycemic effect while also improving cardiovascular function for the patients.
|
31838207 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Drugs acting as glucagon-like peptide-1 receptor agonists (GLP-1RAs) developed for the management of T2DM reduce body weight and liraglutide is the first GLP-1RA to be approved for the treatment of obesity in patients with and without T2DM.<b>Areas covered</b>: In this review of relevant published material, the authors summarize the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of liraglutide for the treatment of obesity.<b>Expert opinion</b>: Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake, independent of its glucose-lowering effects.
|
31790314 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.
|
31699625 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
PubMed, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) comparing SGLT2is plus Dipeptidyl-Peptidase 4 inhibitors (SGLT2is/DPP4is) or glucagon like peptide-1 receptor agonists (SGLT2is/GLP-1RAs) against SGLT2is as monotherapy or add-on to metformin in T2DMs.
|
31642583 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Nevertheless, prior animal and human studies on incretin mimetics, glucagon like peptide-1 receptor agonists (GLP-1 RA) approved for T2DM treatment, have provided indirect evidence that they may also ameliorate NAFLD/NASH, whereas dipeptidyl dipeptidase-4 inhibitors (DDP-4i) were not better than placebo in reducing liver fat in T2DM patients with NAFLD.
|
30961499 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cardiovascular outcome trials (eg, LEADER [Liraglutide Effect and Action in Diabetes Evaluation of Cardiovascular Outcome Results], SUSTAIN-6) demonstrated that GLP-1 (glucagon-like peptide 1) analogs including liraglutide reduce the risk of cardiovascular events in type 2 diabetes mellitus.
|
31747801 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover, L-SGgly can significantly increase (p < 0.01) GLP-1 levels and decrease (p < 0.01) IL-6 levels in T2DM rat serum.
|
31586692 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.
|
31673896 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Insulin degludec/liraglutide (IDegLira) is a fixed-ratio combination (FRC) of basal insulin and glucagon-like protein-1 receptor agonist (GLP-1 RA) that has demonstrated glycemic and metabolic benefits in patients with type 2 diabetes mellitus (T2DM) in both randomized controlled trials and real-world studies.
|
31808132 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This was a prospective cohort study that examined change in lung function measurements over two years of T2DM patients (n = 32) treated with metformin monotherapy (control cohort), metformin plus GLP-1R agonists (GLP-1R agonists cohort), or metformin plus insulin (insulin cohort).
|
31228775 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recently GIP-GLP-1 co-agonists with powerful effects on glycemic control and body weight in patients with type 2 diabetes have been described.
|
31838219 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with type 2 diabetes.
|
31422062 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although none of the trials are fully representative of the general population, among the four trials examined, results from baseline REWIND were found to be more generalizable to the US adult T2D population than those of other GLP-1 RA CVOTs.
|
30714309 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 based therapies was performed on cardiovascular outcomes.
|
30823882 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms.
|
31640705 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.
|
30565096 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Altered GLP-1 secretion from L cells has been implicated in the development of type 2 diabetes mellitus and its resolution following bariatric surgery.
|
30660763 |
2019 |